Intercept Ends NASH Development, But Other Firms’ FXR Agonist Programs Ongoing

 
• By Joseph Haas
  
Dominoes
Intercept followed a second CRL by announcing its exit from NASH R&D • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from New Products

More from Scrip